1. Home
  2. KZIA
  3. KZIA Forecast

as of 12-04-2025 3:32pm EST

$13.05
$0.20
-1.51%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Frequently Asked Questions

Learn more about our KZIA ML prediction model

What parameters are used to train the KZIA ML model?

Our stocks KZIA ML model is trained using historical data with over 25 parameters, including volume indicators, volatility indicators, momentum indicators, trend indicators, and other technical metrics.

How often is the KZIA ML model updated?

We update our ML model weekly or biweekly (depending on market capitalization) using TensorFlow, typically over the weekend to ensure the most current predictions.

Why might the model accuracy vary?

Our current data provider offers limited historical data, which can impact accuracy. As we continue to gather more data and add additional indicators, we expect the model's accuracy to improve over time.

How can I contribute data to improve accuracy?

We greatly appreciate contributions! Please contact us at info@finquota.com to discuss how you can help improve our models.

Are shorter timeframe predictions available?

Yes, we offer predictions for strategy purposes with shorter intervals including 1 minute, 2 minutes, 5 minutes, 15 minutes, and 30 minutes timeframes.

Should I use this for financial decisions?

Our ML model is designed for educational purposes only and should not be used as the sole basis for financial decisions. Always consult with a qualified financial advisor before making any investment decisions.

Share on Social Networks: